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Abstract 
Background: Unadjusted survival on Renal Replacement Therapy (RRT) varies widely from centre to 
centre in England. Until now, missing data on case-mix has made it impossible to determine whether 
this variation reflects genuine differences in the quality of care. Data linkage has the capacity to 
reduce missing data. 
Methods: Modelling of survival using Cox proportional hazards of data returned to the UK Renal 
Registry on patients starting RRT for established renal failure in England. Data on ethnicity, 
socioeconomic status and comorbidity were obtained by linkage to the Hospital Episode Statistics 
database, using data from hospitalisations prior to starting RRT. 
Results: Patients with missing data were reduced from 61% to 4%. Prevalence of co-morbid 
conditions was remarkably similar across centres. When centre-specific survival was compared after 
adjustment solely for age, survival was below the 95% limit for 6/46 centres. Addition of variables 
into the multivariable model altered the number of centres that appeared to be  ‘ŽƵƚůŝĞƌƐ ?ǁŝƚŚǁŽƌƐĞ
than expected survival as follows: ethnic origin 4 outliers, socioeconomic status 8 outliers and year 
of start of RRT 4 outliers. The addition of a combination of 16 comorbid conditions present at the 
start of RRT reduced the number of centres with worse than expected survival to one. 
Conclusions: Linked data between a national registry and hospital admission data dramatically 
reduced missing data, and allowed us to show that nearly all the variation between English renal 
centres in three-year survival on RRT was explained by demographic factors and by co-morbidity.  
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Short Summary 
Centre specific outcomes which are affected by case mix should be adjusted for comparison, but 
variable data completeness prevents this. Data completeness for important demographic variables 
was improved from 39% to 96% by linking UK Renal Registry and hospitalisation data, enabling 
comprehensively adjusted centre specific survival reporting and reducing the number of centres with 
worse than expected survival from six to one. 
 
Address for Correspondence 
Dr James Fotheringham 
James.fotheringham@nhs.net 
 
Keywords 
Renal Replacement Therapy, Survival, Performance Measures, Open data, Data linkage 
  
5 
 
Introduction 
Renal replacement therapy (RRT) for established renal failure (ERF) is currently administered to 
approximately 40,000 patients in England, at a cost of three quarters of a billion pounds per year(1). 
Recognising the potential association between the attainment of clinical and laboratory targets and 
improvements in hard endpoints (2), the UK Renal Registry (UKRR) regularly benchmark the 67 
centres providing RRT in the UK against standards recommended by national and international 
governing bodies and guidelines(3). Identification of poor centre performance has prompted 
investigation and improvement. The UK stands apart from other countries in the reporting of centre 
or healthcare provider specific outcomes in such detail (4). 
However, the cornerstone of centre specific reporting is uniform data quality and completeness, and 
variation in these has prevented the UKRR from generating comprehensively adjusted and inclusive 
centre specific performance indicators. Reporting of outcomes without adequate adjustment for 
case mix may increase or decrease the apparent variation in performance between centres, and 
result in inappropriate labelling of providers as delivering poor care. 
Barriers in data quality and completeness are not unique to renal services or UK data collections and 
registries (5-7). However, other demographic patient information exists within the healthcare 
system, either routinely collected or as part of other disease registers. This study uses a disease 
registry, the UKRR, of patients receiving RRT between 2002 and 2006 linked to routine data on 
hospitalisation from 1998 to 2011 extracted from the Hospital Episode Statistics (HES) database. The 
goal is to report comprehensively adjusted centre specific incident survival on RRT, with a view to 
understanding the variation in survival in English renal centres. 
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Materials and Methods 
Participants and Linkage 
This is a cohort study of all RRT patients over the age of 18 and comprises all patients who started 
RRT for ERF in English renal centres between 1
st
 of January 2002 and the 31
st
 of December 2006. It 
gained ethical approval from the South East Research Ethics Committee in October 2010. The cohort 
was identified from the UKRR database, derived from data extracts from renal centres throughout 
the UK, and is subject to extensive data validation and cleaning prior to analysis (8). Patients who 
started RRT and did not have a recovery of renal function lasting more than 90 days within 90 days 
of starting were identified and their demographic data extracted including data on changes in 
treatment modality and death collected until 31
st
 of December 2009. This export was encrypted and 
transferred to a third party agency responsible for the process of linkage, the Research Capability 
Programme (RCP) Pilot Health Research Support Service. 
 
The RCP had already taken receipt of the HES dataset from April 1996 to February 2011, and Office 
of National Statistics death registrations over a similar period. Data sources were linked by validating 
National Health Service (NHS) numbers where possible using the NHS Personal Demographics 
Service (PDS), then linked on NHS number and date of birth. In situations where the NHS number 
existed in the datasets but could not be traced additional checks against patient details were 
performed.  
As HES only covers hospitalisation in England, patients receiving care in English units with postcodes 
outside England were excluded. As the goal of the analysis was adjusted survival reporting, patients 
were excluded from analysis if adjustment variables were missing: where ethnicity or socioeconomic 
status could not be derived from either source or there were no admissions prior to start of RRT. The 
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absence of hospitalisation prior to the start of RRT is rare, may represent data linkage issues, or 
would necessitate the patient to be labelled as having no comorbidity which may be inaccurate.  
Demographic Variables including Comorbidity 
The ethnicity scheme employed by UKRR was mapped into that used by HES when collection began 
in 1998, and further simplified into White, Black, South Asian and Other. HES was used as the 
primary source with the UKRR dataset queried in situations when ethnicity was coded missing. 
Socioeconomic status was determined from both datasets using geographical data from 6 months 
before to 6 months after the start of RRT, in the form of the index of multiple deprivation (IMD) 
version 2004 (9), which ranks 32,482 geographical areas in England by deprivation. This was grouped 
by quintiles. When sources differed the most deprived value was used. 
Comorbidity at starting RRT was determined from comorbid conditions as coded by International 
Classification of Disease version 10 (ICD10) from all diagnosis fields in all hospitalisation admissions 
prior to starting RRT. Comorbid conditions were identified from the Charlson comorbidity index(10) 
and the Elixhauser measure(11) using ICD10 codes from existing literature(12). Conditions collected 
by UKRR that did not exist in the Charlson or Elixhauser schemes were identified from the NHS 
Information Centre HRG grouping document which includes all ICD10 and Office of Population 
Censuses & Surveys (OPCS) procedural codes currently employed. Duplicate or overlapping 
conditions were excluded and only conditions with a prevalence of two per cent or more were 
explored.  
Information on primary renal disease (PRD) returned by centres was enhanced with hospitalisation 
data from six months before to six months after date of start of RRT. The ICD10 codes of 48 causes 
ŽĨWZǁĞƌĞŵĂƉƉĞĚƚŽƚŚĞƐĞǀĞŶh<ZZWZŐƌŽƵƉƐĂŶĚƉĂƚŝĞŶƚƐǁŝƚŚŵŝƐƐŝŶŐŽƌ ?ƵŶŬŶŽǁŶ ?WZ
were filled in if relevant codes were identified. 
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Statistical Methods 
Only patients surviving beyond 90 days from the date of first RRT were analysed due to issues with 
variable centre reporting of patients dying within 90 days and recognition that episodes of acute 
kidney injury which may have recovered function will have been censored(13). Patients were 
assigned to the first centre they received treatment for the duration of the study. Survival was 
modelled using Cox proportional hazards in R(14). To facilitate comparison between centres and as 
per existing UKRR practice, censoring at the time of transplantation was not performed and patients 
transplanted before starting dialysis were included in the analysis. Centres with a high proportion of 
South Asian or Black origin are likely to have a healthier dialysis population, because South Asian and 
Black patients are less likely to undergo early transplantation(15). 
Manual addition of age, gender, ethnicity, socioeconomic status and comorbid conditions of greater 
than two percent prevalence was employed to determine an appropriate model, with statistically 
significant variables being retained. To determine renal centre specific survival at three years a cox 
model including the variables of interest and the centre as a variable was generated. With this 
model, survival of a patient in each centre was predicted by varying the centre variable. The patient 
was coded as white, aged 65, male, of the most deprived socioeconomic group, having started RRT 
in 2002, and with individual comorbid conditions defined as absent. The proportion alive at three 
years of patients of this demography and comorbidity was reported as the centre-specific survival. 
Interactions between age and diabetes(16), diabetes and cardiovascular disease and ethnicity and 
diabetes was explored with interaction terms. Testing for the constant risk fallacy (17) was 
performed by fitting an interaction between centre and the candidate comorbid conditions, in 
addition to age, ethnicity, socioeconomic status and year of start. If the interaction term was 
significant, it suggested the mortality risk of a comorbid condition was not constant across all renal 
centres. Mean comorbid scores were compared with the independent t-test. 
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As renal centres vary in the number of incident patients they take on across England, a funnel plot 
was used to determine whether a centre was deemed to have better or worse survival than the 
average. Firstly the proportion of patients alive at three years derived from the Cox proportional 
hazards model for a centre was plotted against the size of the centre. The outlier limits of 95% and 
99.8% were derived using the binomial distribution, with centre outlier status explored on the funnel 
plot with the addition of individual variables (18).  
To index the overall comorbid burden per patient to allow a simple comparison between centres, 
weights for the presence of individual conditions were determined from a Cox proportional hazards 
model factoring age, sex and the presence or absence of statistically significant candidate 
comorbidities. Multivariate hazard ratios for comorbid conditions were converted into scores as per 
previously reported methods(19). They were summed to create an overall score using the following 
bandings and weights: hazard 1.2 - A? ? ? ? P ? ?A? ? ? ?- <2.5 : 2, 2.5 - A? ? ? ? P ? ?A? ? ? ?- <4.5 : 4. Conditions 
with a hazard of less than 1.2 were not assigned a score. 
 
Results 
Participants 
21,633 ERF patients were identified in 46 renal centres in England, of which 19,525 patients survived 
to 90 days. 18,798 (96.2%) had admission HES data prior to the start of RRT and no missing data for 
ethnicity and socioeconomic status following dataset combination. The final analysis cohort 
including hospitalisation data is detailed in figure 1. Mean follow-up time was 30.5 months. Patients 
with complete data from the UKRR alone accounted for 39% of the cohort. At three years, 11.1% of 
the total cohort had changed centres, but only 4.4% of those not transplanted. 
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Patient demography including the overall prevalence of individual comorbid conditions, and number 
of centres with higher and lower than average prevalence for individual comorbidities are detailed in 
table 1. As illustrated in figure 2 there was wide variation in the ethnic mix of the renal centres. Of 
note, the comorbid conditions with the greatest range of prevalence between centres were diabetes 
(23.9  ? 45.2%), stroke (3.2  ? 16.1%), and heart failure (7.8  ? 25.0%), but the overall mean comorbid 
score was similar across centres (figure 3). The presence of diabetes was associated with greater 
hazard for death in patients under 55 than other age groups (<55 years hazard for diabetes 3.307, CI 
2.89  ? 3.79; 55 - 65 years hazard 1.71, CI 1.52  ? 1.92; > 65 years hazard 1.09, CI 1.02  ? 1.16)). 
Interactions between diabetes with CVD and with ethnicity were not statistically significant. The 
proportion surviving at 3 years adjusted to age 65 was 74.5% (95% CI 73.7  ? 75.4%) in those with 
UKRR comorbidity completed and 64.3% (95% CI 63.2  ? 65.3%) in those with UKRR comorbidity 
missing. Lymphoma and depression (derived by HES) were the only conditions more common in 
patients with UKRR comorbidities missing (lymphoma: 3.8% in comorbidity missing vs 3.0% in 
comorbidity completed, P=0.001, depression: 2.7% in comorbidity missing vs 2.1% in comorbidity 
completed, P=0.006). These were sufficient to separate the groups when comparing comorbid score. 
The mean comorbid score was 1.10 in those with UKRR comorbid data vs 1.22 in those without (CI 
on the difference 0.08  ? 0.15, P<0.001). 
 
The univariate and multivariate hazard ratio of death relative to the absence of the individual 
comorbid conditions and their associated comorbid score is detailed in table 2. The prevalence of 
comorbid conditions and mean comorbid score demonstrated small variation across ethnic groups 
illustrated in table 3. Black patients had a significantly lower comorbid score overall, but the burden 
of comorbidity across White, South Asian and Other ethnic groups was similar, despite the worse 
survival in the White ethnic group.  
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The Impact of Demography on Centre-Specific Survival 
Centre specific survival adjusted to age 65 years but with no adjustment for other demography or 
comorbidity is plotted in figure 4a, identifying six centres with worse than expected survival. The 
addition of ethnicity to the age only model reduced the dispersion of centre survival, with four 
centres remaining outliers. Socioeconomic status identified four additional outliers, bringing the 
total to eight, with these new outliers returning to within the 95% control lines once year of start 
was included. Funnel plots detailing outlying centres with adjustment for age, ethnicity, 
socioeconomic status and year of start of RRT are shown in figure 4b. The addition of 16 comorbid 
conditions with a statistically significant influence on comorbidity in addition to the above variables 
were added reducing the number of outlying centres with low survival to one (figure 4c). Centre 
reported primary renal disease enhanced by hospitalisations in the twelve months around the start 
of RRT (20) improved model fit but failed to explain the one remaining outlying centre. 
 
Given the limited effect of the addition of certain comorbid conditions to the number of outliers, 
combinations of individual conditions were explored to determine the minimum necessary comorbid 
conditions required to achieve similar adjustment to a comprehensive model. The inclusion of COPD, 
previous myocardial infarction, congestive cardiac failure and the Diabetes-Age interaction in 
addition to age, ethnicity, socioeconomic status and year of start of RRT were sufficient to result in 
no outlying centres, masking the worse than expected survival in one centre identified with the 
comprehensive model including all comorbid conditions.  
 
Non-constant risk across centres 
The constant risk hypothesis was explored by examining the interaction of risk factors with centres. 
The comorbidities of previous myocardial infarction, valvular heart disease and claudication showed 
statistically significantly different hazard ratios for different centres when modelled with age, 
ethnicity, socioeconomic status and year of start. However following the addition of the conditions 
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of stroke, congestive cardiac failure, COPD and the diabetes-age interaction term non-constant risk 
persisted in valvular heart disease only. 
 
Modelling survival to three years using demography and comorbidity with exclusion of conditions 
identified as having non-constant risk resulted in the identification of the same one outlying centre 
with worse than expected survival. 
 
Information on agreement between data sources, extended linkage methodology, model 
performance measures and the effect of censoring for transplantation the inclusion are available in 
supplementary materials. 
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Discussion 
In an effort to adjust renal unit centre survival figures for case-mix we linked all incident patients 
starting RRT between 2002 and 2006 to the HES database covering England, reducing patients with 
missing data from 61% to 3.8%. We have been able to report the most comprehensively adjusted 
centre specific survival for English renal centres to date and reduce apparent variation in survival 
between centres. 
When considering centre specific adjusted reporting, one could argue if a demographic characteristic 
or comorbid condition has an impact on survival, is outside the control of a centre, and it varies 
across centre, it should be adjusted for. The ability to report a composite measure of comorbidity 
has allowed us for the first time to compare the case-mix of patients accepted onto RRT across 
England. The similar centre specific mean comorbid score across centres argues against variation in 
the type of patient taken on by an individual centre, for instance due to resource constraints and 
subsequent rationing of dialysis services(21). The variation in ethnicity and its established impact on 
survival (22) (23) mirrored in this study highlights the importance of ethnicity as an adjustment 
variable, however variation in risk across age groups tested for by interactions was not identified 
(24). The impact of ethnicity on centres mandates a high level of data completeness to enable 
adjustment. 
Although other studies have highlighted the small impact comorbidity has in explaining variation in 
survival (25), the impact of case-mix adjustment for the individual should not be understated. Using 
the proposed model 70% of white patients with diabetes aged 65 survive to three years whereas 
76% (difference 6%, 95% CI of difference 2-9%) of South Asians with the same case-mix survive to 
the same timepoint. If the patients had previous myocardial infarction and cardiac failure three year 
survival drops to 55% in the white and 63% in in the South Asians (difference 8%, CI of difference 2-
13%) at three years. In addition, a degree of model precision is required to identify or explain 
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outlying centres. Although the variables used for adjustment differ, our model prediction 
performance (C-statistic excluding centre 0.775, CI 0.769  ? 0.782, available in supplementary data) is 
superior to that reported at three years using US data (0.669) (26), and one year using Canadian data 
(0.765).  
 
Reassurance is gained from the fact that survival in English renal centres is largely similar when all 
variables are taken into consideration, highlighting importance of comprehensive data collection. 
The residual variation in risk associated with some cardiovascular diseases such as myocardial 
infarction, valvular heart disease and claudication may imply a difference in how these conditions 
are managed in these renal centres or surrounding NHS trusts. Such non-constant risk may be 
explained by genuine differences in the hazard for mortality in the geographical areas that these 
renal centres serve (17). A more likely explanation is the variation in the coding quality across NHS 
trusts in England. HES data quality has been the subject of discussion for some years, with a body of 
work highlighting reasonable accuracy (27) and predictive ability (28). ŶŝŶĐƌĞĂƐĞŝŶĐŽĚŝŶŐ ?ƋƵĂůŝƚǇ ?
manifested by the number of coding fields used per admission was observed in this study over time 
(20), and some of the improvements seen in the hazard for death for year of start of RRT is likely to 
reflect this over and above improvements in clinical care. This study has been able to recommend a 
minimum adjustment specification to adequately explain or highlight outliers, should future linkage 
not be possible or concerns over the validity of HES preclude its use. 
Limitations beyond the quality of HES data in this study include at this time our inability to report 
adjusted survival in Scotland, Wales and Northern Ireland. The lack of adjustment for late 
presentation or unplanned starts on RRT (29) was necessary as even in combination these datasets 
fail to robustly capture this in all centres. Other registry reports show a greater burden of 
comorbidity in those arriving late or in an unplanned start (30), and adjustment for comorbidity may 
represent a surrogate for this. Our inclusion of primary renal disease is purely experimental as 
15 
 
prevalence of unknown PRD across centres varied significantly. Our decision not to censor for 
transplantation may be contentious, but pre-emptive transplantation, timely deceased donor 
transplantation and living donor transplantation are all within a centres control. Also lacking from 
our analysis is the influence of quality of care after initiation of RRT on outcomes; however, these 
models and the data informing them give us the opportunity to study these processes. 
This study highlights that routine linked data can be used to overcome missing data in disease 
registries, enabling performance measurement and initiating investigation and driving improvement 
when significant unexplained variation is identified. Some centres which have previously been 
identified as having unadjusted inferior survival may have been targeted inappropriately. 
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Tables 
Table 1 ʹ Demographics, comorbidity prevalence and number centres outlying for 
comorbidity prevalence. n=18,798 
 
Prevalence 
(%) 
Centre Specific 
Prevalence 
Range (%) 
Outliers 
(centres 
high/centres 
low, out of 46) 
Age  (mean, range) 60.1 (18 - 94) - - 
Sex (female) 37.2 - - 
Race  - - 
White 81.4 - - 
Black 5.6 - - 
South Asian 6.5 - - 
Other 6.5 - - 
Comorbid Conditions    
No Comorbid Conditions    
COPD            5.2 1.6  ? 12.9 5 / 7 
Arrhythmia             3.6 1.3  ? 8.1 3 / 2 
Heart Failure              14.9 7.8  ? 25.0 4 / 5 
CABG      4.9 0.9  ? 9.8 5 / 4 
Depression             2.4 0  ? 4.8 1 / 1 
Stroke              7.7 3.2  ? 16.1 5 / 6 
Myocardial Infarction            11.9 6.8  ? 19.4 5 / 4 
Lymphoma             3.4 1.0  ? 6.8 2 / 1 
Neurological Disease             3.8 1.2  ? 11.3 3 / 3 
Vascular Procedure        3.5 1.2  ? 7.1 3 / 4 
Valvular Heart Disease          3.7 1.1  ? 10.0 5 / 5 
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Cancer              6.8 4.5  ? 14.5 2 / 2 
Connective Tissue Disease    3.4 0  ? 6.1 3 / 1 
Peptic Ulcer Disease              4.7 1.7  ? 8.5 6 / 2 
Claudication 7.1 2.5  ? 14.5 7 / 6 
Diabetes       31.6 23.9  ? 45.2 7 / 5 
Note: Summary statistics reported as proportions unless stated otherwise 
Centre outliers are defined as those centres with a prevalence of the comorbidity that falls outside the 95% 
limits for a funnel plot derived from the binomial distribution, centred around the national mean. 
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Table 2 ʹHazard ratio of death associated with patient characteristics and comorbid score. 
 
Hazard Ratio for Death 
(Univarate) (95% CI) 
Hazard Ratio for Death 
(Adjusted) (95% CI) 
Comorbidity 
Score 
Age (per decade) 1.27 (1.25 - 1.28) 1.23 (1.22 - 1.24)  
Sex (female) 0.98 (0.93 - 1.03) 1.05 (1.00 - 1.11)  
Race    
White 1 (ref) 1 (ref)  
Black 0.44 (0.38 - 0.51) 0.55 (0.47 - 0.64)  
South Asian 0.67 (0.59 - 0.75) 0.78 (0.69 - 0.88)  
Other 0.52 (0.46 - 0.59) 0.65 (0.57 - 0.74)  
Socioeconomic Status    
1 - Most Deprived 1 (ref) 1 (ref)  
2 1 (0.92 - 1.08) 0.95 (0.88 - 1.03)  
3 1 (0.92 - 1.09) 0.88 (0.81 - 0.95)  
4 1.12 (1.03 - 1.21) 0.92 (0.85 - 1)  
5 - Least Deprived 1.03 (0.95 - 1.12) 0.85 (0.78 - 0.93)  
Year    
2002 1 (ref) 1 (ref)  
2003 0.96 (0.88 - 1.05) 0.98 (0.90 - 1.07)  
2004 0.92 (0.85 - 1) 0.89 (0.82 - 0.97)  
2005 0.87 (0.8 - 0.94) 0.8 (0.74 - 0.88)  
2006 0.83 (0.76 - 0.9) 0.78 (0.71 - 0.84)  
Comorbid Conditions    
COPD            2.19 (2.01 - 2.39) 1.34 (1.23 - 1.47) 1 
Arrhythmia             1.87 (1.67 - 2.08) 1.16 (1.04 - 1.3) 0 
Heart Failure              2.27 (2.14 - 2.41) 1.39 (1.3 - 1.48) 1 
CABG      1.23 (1.11 - 1.37) 0.81 (0.72 - 0.91) 0 
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Depression             1.54 (1.34 - 1.77) 1.55 (1.34 - 1.79) 2 
Stroke              1.77 (1.64 - 1.92) 1.26 (1.16 - 1.36) 1 
Myocardial Infarction              1.95 (1.83 - 2.08) 1.2 (1.11 - 1.29) 1 
Lymphoma             3.85 (3.51 - 4.23) 3.48 (3.16 - 3.83) 3 
Neurological Disease             1.43 (1.27 - 1.6) 1.52 (1.35 - 1.71) 2 
Vascular Procedure        2.1 (1.89 - 2.34) 1.27 (1.13 - 1.42) 1 
Valvular Heart Disease             1.9 (1.71 - 2.12) 1.3 (1.16 - 1.45) 1 
Cancer              1.95 (1.8 - 2.11) 1.39 (1.28 - 1.51) 1 
Connective Tissue Disease        1.25 (1.1 - 1.43) 1.34 (1.18 - 1.53) 1 
Peptic Ulcer Disease              1.7 (1.54 - 1.87) 1.17 (1.06 - 1.29) 0 
Claudication 2.03 (1.88 - 2.2) 1.19 (1.09 - 1.29) 0 
Diabetes       1.47 (1.4 - 1.55) 1.44 (1.36 - 1.52) 1 
Comorbid Score derived from multivariate hazard ratio (see methods), hazards of less than 1.2 are 
not assigned scores for centre comorbid burden comparison but all significant variables are 
included in the model. 
Variables included in adjusted hazard ratio: Age, sex, ethnicity, socioeconomic status, year of start 
of renal replacement therapy. 
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Table 3 ʹ Prevalence of comorbidities according to ethnicity and overall comorbid score 
 
All Patients 
(18,798) 
White 
(81.4%, 15,309) 
Black 
(5.6%, 1,054) 
South Asian 
(6.5%, 1,214) 
Other  
(6.5%, 1,221) 
Chi-Squared 
P value 
Comorbidities        
Diabetes 31.6 (5,944) 28.6  39.5  49.7  45.2  <0.001  
Myocardial 
infarction 11.9 (2,229) 12.1  5.8  13.6  12.3  <0.001 
CABG 4.9 (919) 4.7  1.8  8.2  7.3  <0.001 
Heart Failure 14.9 (2,803) 14.7  14.5  16.8  15.4  0.25 
Claudication 7.1 (1,344) 7.9  3.3  3.8  5  <0.001 
Valvular Heart 
Disease 3.7 (697) 3.9  2.3  2.8  3.1  0.007  
Stroke 7.7 (1,446) 7.7  7.5  7.9  7.2  0.90 
COPD 5.2 (978) 5.8  0.9  3.3  3.8  <0.001 
       
Comorbid Score 
(mean, 95% CI) 
1.11  
(1.09 - 1.13) 
1.12  
(1.1 - 1.14) 
0.99  
(0.91 - 1.07) 
1.11  
(1.05 - 1.17) 
1.15 
(1.07 - 1.23)  
CABG: Coronary artery bypass graft 
Comorbid Score derived from multivariate hazard ratio (see methods) 
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Figures 
 
Figure 1. Data linkage and inclusion of patients in analysis 
 
Incident RRT Patients 
2002  ? 2006 
N=21,633 HES Inpatient Spells 
N=2,818,193 
ONS Registered Deaths 
N=11,546 
Remaining cohort 
N=21,271 
Surviving beyond 90 days 
N=19,585 
Excluded patients 
Duplicates (12 records) 
Non-English Residences (201 patients) 
No Linked HES Data (149) 
Remaining patients 
N=18,798 
Missing Ethnicity (151) 
Missing Socioeconomic Status (288) 
Missing Comorbidity (288) 
26 
 
Figure 2. English renal units, catchment areas and variation of ethnicity in renal 
replacement therapy patients between 2002 ʹ 2006 by Local Authority 
 
 
Catchment area methodology: The renal centre receiving the greatest number of incident patients 
from an individual local authority is assigned the local authority as part of its catchment area. Colour 
represents the proportion white in the centre serving the catchment area. 
  
27 
 
Figure 3. Mean comorbid score using weighted comorbid conditions for 46 renal centres in 
England. 
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Figure 4. 
Funnel plots detailing centre specific three year survival following adjustment 
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A) Centre specific predicted survival at three years adjusted for age and sex. 
Mean Centre-Specific Survival at three years adjusted to age 65 and male: 69.7%, range 60.2 
 ? 78.7%. Six centres with worse than expected survival highlighted. 
 
B) Centre specific survival adjusted for age, sex, ethnicity, socioeconomic status and 
year of start of renal replacement therapy. 
Mean Centre-Specific Survival at three years adjusted to white 65 year old male in most 
deprived group starting renal replacement therapy in 2002: 67.9%, range 60.5  ? 75.02%. 
Four centres with worse than expected survival highlighted. 
C) Centre specific survival adjusted for age, sex, ethnicity, socioeconomic status, year 
of start of renal replacement therapy and 16 comorbid conditions 
Mean Centre-Specific Survival at three years adjusted to all characteristics including 
demography and comorbidity: 78.8%, range 72.9  ? 86.3%. One centre with worse than 
expected survival highlighted. 
 
